Researchers use DNA origami to generate tiny mechanical devices that deliver a drug that cuts off the blood supply to tumors in mice.
Industry layoffs may save a few dollars, at the cost of losing the collective brainpower of thousands of scientists.
May 1, 2015|
© DUSAN PETRICIC
Have you ever been laid off? It happened to me for the first time this February, along with a considerable number of my colleagues, two years after my longtime employer—a truly innovative and forward-thinking midsize pharmaceutical company—was purchased by a larger pharma company. As is customary in such situations, a security guard escorted me to my office, where I was instructed to pack my things into two cardboard boxes. It was an altogether surreal experience, one that some of you may know all too well. Layoffs have become an unfortunately familiar part of life in the pharmaceutical industry, and R&D is always low-hanging fruit in such situations, as we do not make money for the company in the short term. Scientists continue to be let go at an alarming rate, and are often unable to find work no matter their level of experience.
The evening of my layoff I found myself sitting on the roof of my car repairing the light in my garage door opener. Of course, it had chosen that day to malfunction. As I was soldering in the door opener’s new logic board, I started thinking about all of the other laid-off scientists and about the waste of collective brainpower. Even those who haven’t been let go, or who are able to find new jobs, are feeling more and more restricted and limited in their research, constantly oppressed by the pressure to do more with less and in less time. It seems that industry has forgotten that science takes time, and when you push it, bad things often happen.
And so I decided to explore the ramifications of layoffs both on a personal and societal level. I talked with several of my scientist friends and former colleagues, including academics and those working in industry, from bench scientists all the way up to senior VPs. I also spoke with current and future graduate students and to people tangentially associated with R&D, including project managers and quality-control professionals. What I found was a creativity and productivity drain—an enormous underutilization of brainpower that could and should be answering the most challenging questions facing the human race and the planet.
Scientists who are lucky enough to be employed are finding their creativity and ingenuity stunted by shrinking R&D budgets and
a lack of autonomy.
A scientist out of work is like a fire with nothing to burn. Problem solving and exploration are the fuel that keeps our fires burning—hence my garage-door-opener–fixing session the day I was laid off. Having something to fix and puzzle over kept my mind occupied and got me through a difficult time far more effectively than any movie or television show could have. I found this a common theme in the conversations I had with other laid-off researchers over the next few weeks. One of the scientists I spoke with has been looking for work for more than a year and talked of how he missed the intellectual stimulation even more than the paycheck.
I also found that those scientists who are lucky enough to be employed are finding their creativity and ingenuity stunted by shrinking R&D budgets and a lack of autonomy. They spoke of how rarely they were asked for their opinions and how increasingly common it was to have decisions supposedly based on science made by nonscientists. They also spoke of the ever-present worry about being laid off and what that would mean not just for them, but for their research projects. Typically, there is no debriefing when a researcher is laid off, and much of the “soft” information gathered over the life of the project—such as ideas jotted down on scrap paper or knowledge stored away in the scientist’s head—is lost.
For some, the unsteady pharmaceutical research environment became too much to bear. One senior-level scientist with decades of experience decided to leave science altogether after suffering the consequences of repeated mergers. Others were driven back to academia, such as the former president of a major biotech company who decided to leave his position and return to the bench at a local university, realizing that his brain needed an outlet that he could not find in the confines of upper management. But even academia is no safe haven from economic pressures. When I spoke to academic researchers, I heard less about autonomy and job security than about the never-ending grant application process, the dismal pay for bench scientists and postdocs, and the increasing level of bureaucracy pulling scientists away from research and into meetings that appear to accomplish very little.
Focusing solely on the bottom line while not taking into careful consideration the impact that R&D cutbacks and layoffs will have on the scientitfic, technological, and therapeutic advances of the future will cost us far more than money.
I also talked with present and future graduate students, who spoke of being lured away by parents and teachers into professions with greater security and higher pay. After all, there are far more lucrative and easier fields than science for these young men and women to enter. It is imperative that, instead of redirecting these incredible young minds, we nurture their talent and enthusiasm for scientific research. If we do not, we risk losing an entire generation of potential.
But there is hope found in research centers around the world that are transforming how we conduct science. Take, for example, the not-for-profit Cell Therapy Catapult in London, established in 2012 as a center of excellence in innovation. Its mission is to “drive the growth of the industry by helping cell therapy organizations across the world translate early-stage research into commercially viable and investable therapies.” It bridges the often difficult divide between academic institutions, for-profit businesses, and other research communities. In other words, it allows scientists to be their most creative and productive while in turn advancing the business of cell therapy. This model, and models similar to it, could and should be utilized in other research disciplines. Collective brainpower is an invaluable commodity.
We all know that drug development, clinical trials, and other aspects of biomedical research are extremely expensive. Yet focusing solely on the bottom line while not taking into careful consideration the impact that R&D cutbacks and layoffs will have on the scientific, technological, and therapeutic advances of the future will cost us far more than money. We will lose generations of scientists to other careers, and with them the breakthroughs, cures, and pure genius that will shape our collective tomorrows.
Sarah Ramsay is a biochemist and cell biologist living in Fort Worth, Texas. She has spent the last 11 years working in the field of regenerative medicine with an emphasis on wound healing.
May 19, 2015
Scientists need to understand that in our capitalistic system, everything is business. Whether it be working directly for a corporation or to help raise funds for a non-profit or grab those tuition dollars from students in academia, its all about the money. There is no profit in intellectual stimulation for any organization at large. There is no logic in losing money with having too many people on the payrolls. It's a tough world out there. Learn.
"Collective brainpower is an invaluable commodity." Correct, it has no value at all...unless it is focused in a capitalistic manner. The ONLY way for scientists to fight back against the corporate strategic idiocy of massive layoffs is to beat the idiots at their own game. The overbrained, unemployed need to join together to start new companies to come up with new products, treatments, etc. While this idea is almost antithetical to a flock of independants, it's the only way out. Find some friends and start up. Power to the people!
May 19, 2015
Yes it is a waste to put skilled people in any trade or profession out of work when their skills are still badly needed by society. I used to research and teach genetics but retired early to avoid clashing with HR who didn't appreciate my focus on students. One of my ex students who was doing very well in cancer research left a sucessful research career to quick-track to management for job security. He still enjoys presenting the facts and evidence in meetings to good effect. Unfortunately the bottom line of quarterly profits dominates in our management-bonus dominated society.
I do query your term for sacking staff - "let go". Why euphemise? Say fired, even if there was some compensation. Compensation is another euphormism for wages for top management. What are CEOs "compensated" for,? Having to leave their yacht or miss a game of golf?
May 21, 2015
Thank you for your reply. I agree completely. Since writing this article I have spoken to many more leaders in the pharmaceutical industry. Research has changed completely in recent years. The large R&D departments that once dominated in pharmaceutical companies are being either eliminated or significantly downsized. Through these discussions it became clear that big pharma is now primarily outsourcing research through either contract research with CROs, academic collaborations or the purchase and “absorption” of startups. Most scientist jobs today are contract which means little security and no benefits. Simply take a look at the massive increase in scientific “staffing” companies which are basically temp agencies for scientists. It is difficult for me to see how employing someone for five months could lead to any significant progress in the discovery and validation of new therapeutics. That takes years of building on knowledge and experience in the same company on the same project. However, this is the reality. One leader in the pharma industry said the following: “Every morning an employee should ask themselves what tangible value are they brining to the company that employs them. If they are not able to give a concrete response then they need to figure out how to bring value if possible.” If not, the choice is to either be a temp scientist (as their position will most likely be eliminated in the near future), move into management, or to stay in or go back to academia which is facing its own set of problems at present. It is good to remember that your company owes you nothing. As dismal as this may seem, if you are able to handle the risk and uncertainty of being employed at a startup, there is incredible work being done in these hotbeds of innovation. I still have hope for my fellow and future scientists. You simply cannot turn a scientist’s mind off. It will continue to discover…..
August 17, 2015
My son left his job as a biologist because it was literally, as he put it, a dead end job and went to medical school where the money is. He is an M.D. now and the ironic twist is he is collaborating with some University researchers now and he doesn't have to worry about low pay or being fired.